Table 2.

Antimicrobial susceptibility of ESBL non-CRE phenotype Enterobacterales and NME, by country during 2017–21

Organism	n	C/T	IPM/REL	MEM	IPMa	FEP	CAZ	TZP	LVXb	AMK	CST
ESBL non-CRE Enterobacteralesc,d
Belgium	271	88.2	NA	99.6	99.6	15.5	8.5	60.5	34.8	93.0	95.9
Norway	25	96.0	NA	100	100	40.0	8.0	56.0	52.0	100	100
Sweden	77	90.9	NA	100	100	18.2	19.5	62.3	41.3	97.4	100
Switzerland	55	90.9	NA	100	100	16.4	16.4	74.5	38.2	92.7	98.2
Central/northern Europe	428	89.5	NA	99.8	99.8	17.5	11.4	62.4	37.8	94.2	97.2
ESBL non-CRE NMEc,e
Belgium	265	88.7	100	99.6	100	14.3	8.3	59.6	34.2	93.2	98.1
Norway	25	96.0	100	100	100	40.0	8.0	56.0	52.0	100	100
Sweden	77	90.9	100	100	100	18.2	19.5	62.3	41.3	97.4	100
Switzerland	55	90.9	100	100	100	16.4	16.4	74.5	38.2	92.7	98.2
Central/northern Europe	422	89.8	100	99.8	100	16.8	11.4	61.8	37.4	94.3	98.6

C/T, ceftolozane/tazobactam; IPM/REL, imipenem/relebactam; MEM, meropenem; FEP, cefepime; CAZ, ceftazidime; TZP, piperacillin/tazobactam; LVX, levofloxacin; AMK, amikacin; CST, colistin; NA, not applicable or MIC breakpoint not available.

^aThe results provided for ESBL non-CRE Enterobacterales combine % susceptible, increased exposure values for Morganellaceae and % susceptible values for NME.⁶

^bLevofloxacin against Enterobacterales only available for 2018–21.

^cESBL non-CRE was defined by an isolate testing with a ceftriaxone MIC of ≥2 mg/L and an ertapenem MIC of ≤0.5 mg/L.

^d E. coli, K. pneumoniae, K. oxytoca and P. mirabilis.

^e E. coli, K. pneumoniae and K. oxytoca.